Molecular changes induced by the curcumin analogue D6 in human melanoma cells
- PMID: 23642048
- PMCID: PMC3651720
- DOI: 10.1186/1476-4598-12-37
Molecular changes induced by the curcumin analogue D6 in human melanoma cells
Abstract
Background: In a previous report, we described the in vitro and in vivo antiproliferative and proapoptotic activity of a hydroxylated biphenyl (D6), a structural analogue of curcumin, on malignant melanoma and neuroblastoma tumours. In this paper, we investigated the molecular changes induced by such a compound, underlying cell growth arrest and apoptosis in melanoma cells.
Results: To shed light on the mechanisms of action of D6, we firstly demonstrated its quick cellular uptake and subsequent block of cell cycle in G2/M phase transition. A gene expression profile analysis of D6-treated melanoma cells and fibroblasts was then carried out on high density microarrays, to assess gene expression changes induced by this compound. The expression profile study evidenced both an induction of stress response pathways and a modulation of cell growth regulation mechanisms. In particular, our data suggest that the antiproliferative and proapoptotic activities of D6 in melanoma could be partially driven by up-regulation of the p53 signalling pathways as well as by down-regulation of the PI3K/Akt and NF-kB pathways. Modulation of gene expression due to D6 treatment was verified by western blot analysis for single proteins of interest, confirming the results from the gene expression profile analysis.
Conclusions: Our findings contribute to the understanding of the mechanisms of action of D6, through a comprehensive description of the molecular changes induced by this compound at the gene expression level, in agreement with the previously reported anti-tumour effects on melanoma cells.
Figures





Similar articles
-
Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6.BMC Cancer. 2016 May 18;16:317. doi: 10.1186/s12885-016-2362-6. BMC Cancer. 2016. PMID: 27192978 Free PMC article.
-
Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells.Mol Cancer. 2010 Jun 3;9:137. doi: 10.1186/1476-4598-9-137. Mol Cancer. 2010. PMID: 20525240 Free PMC article.
-
Anticancer Activity of Two Novel Hydroxylated Biphenyl Compounds toward Malignant Melanoma Cells.Int J Mol Sci. 2021 May 26;22(11):5636. doi: 10.3390/ijms22115636. Int J Mol Sci. 2021. PMID: 34073232 Free PMC article.
-
Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.Cancer. 2005 Aug 15;104(4):879-90. doi: 10.1002/cncr.21216. Cancer. 2005. PMID: 16007726
-
A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone.BMC Cancer. 2011 Apr 21;11:149. doi: 10.1186/1471-2407-11-149. BMC Cancer. 2011. PMID: 21510869 Free PMC article.
Cited by
-
Phytochemicals for the Management of Melanoma.Mini Rev Med Chem. 2016;16(12):953-79. doi: 10.2174/1389557516666160211120157. Mini Rev Med Chem. 2016. PMID: 26864554 Free PMC article. Review.
-
Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6.BMC Cancer. 2016 May 18;16:317. doi: 10.1186/s12885-016-2362-6. BMC Cancer. 2016. PMID: 27192978 Free PMC article.
-
Use of Polyphenolic Compounds in Dermatologic Oncology.Am J Clin Dermatol. 2016 Aug;17(4):369-85. doi: 10.1007/s40257-016-0193-5. Am J Clin Dermatol. 2016. PMID: 27164914 Free PMC article. Review.
-
Dasatinib enhances curcumin-induced cytotoxicity, apoptosis and protective autophagy in human schwannoma cells HEI-193: The role of Akt/mTOR/p70S6K signalling pathway.Acta Pharm. 2022 Apr 13;72(3):403-414. doi: 10.2478/acph-2022-0025. Print 2022 Sep 1. Acta Pharm. 2022. PMID: 36651538
-
Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.Cells. 2019 Jul 31;8(8):803. doi: 10.3390/cells8080803. Cells. 2019. PMID: 31370278 Free PMC article. Review.
References
-
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AMM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. for the BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516. doi: 10.1056/NEJMoa1103782. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous